Gossamer Bio

Gossamer Bio company information, Employees & Contact Information

Explore related pages

Related company profiles:

Gossamer Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Our goal is to enhance the lives of people living with rare diseases.

Company Details

Employees
172
Founded
-
Address
3115 Merryfield Row,
Email
PR****@****Bio.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
San Diego, California
Looking for a particular Gossamer Bio employee's phone or email?

Gossamer Bio Questions

News

Gossamer Bio to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15, 2025 - Business Wire

Gossamer Bio to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15, 2025 Business Wire

PAH Drug Developer Gossamer Bio Set for Key Presentations at Cantor, Wells Fargo, HC Wainwright Events - Stock Titan

PAH Drug Developer Gossamer Bio Set for Key Presentations at Cantor, Wells Fargo, HC Wainwright Events Stock Titan

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire

XOMA Royalty Acquires Pulmokine, Adding Seralutinib as its Seventh Phase 3 Royalty Asset - Quiver Quantitative

XOMA Royalty Acquires Pulmokine, Adding Seralutinib as its Seventh Phase 3 Royalty Asset Quiver Quantitative

Inside INdiana Business - FinancialContent

Inside INdiana Business FinancialContent

Respira Therapeutics Enters into Agreement with Gossamer Bio (Gossamer) Granting Gossamer Option to Acquire Respira from Samsara BioCapital - PR Newswire

Respira Therapeutics Enters into Agreement with Gossamer Bio (Gossamer) Granting Gossamer Option to Acquire Respira from Samsara BioCapital PR Newswire

Gossamer Bio Announces Second Quarter 2025 Financial Results and Provides Business Update - Business Wire

Gossamer Bio Announces Second Quarter 2025 Financial Results and Provides Business Update Business Wire

Gossamer Bio: A Critical Year Ahead (NASDAQ:GOSS) - Seeking Alpha

Gossamer Bio: A Critical Year Ahead (NASDAQ:GOSS) Seeking Alpha

Gossamer Bio’s Bold Progress: Buy or Pass? - StocksToTrade

Gossamer Bio’s Bold Progress: Buy or Pass? StocksToTrade

Gossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On‑Demand Vardenafil for Pulmonary Hypertension - Business Wire

Gossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On‑Demand Vardenafil for Pulmonary Hypertension Business Wire

Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025 - Business Wire

Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025 Business Wire

Gossamer Bio to Present Preclinical Data at the American Thoracic Society (ATS) 2025 International Conference - Business Wire

Gossamer Bio to Present Preclinical Data at the American Thoracic Society (ATS) 2025 International Conference Business Wire

Gossamer Bio Announces Completion of Enrollment in Registrational Phase 3 PROSERA Study for the Treatment of PAH - Business Wire

Gossamer Bio Announces Completion of Enrollment in Registrational Phase 3 PROSERA Study for the Treatment of PAH Business Wire

Gossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA Study - Business Wire

Gossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA Study Business Wire

Gossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update - Business Wire

Gossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update Business Wire

Gossamer Bio: Initiating Hold As Late‐Stage Data Nears Inflection (GOSS) - Seeking Alpha

Gossamer Bio: Initiating Hold As Late‐Stage Data Nears Inflection (GOSS) Seeking Alpha

XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements - Yahoo Finance

XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements Yahoo Finance

Gossamer Bio: Bullish Ahead Of Seralutinib's Phase 3 Readout (NASDAQ:GOSS) - Seeking Alpha

Gossamer Bio: Bullish Ahead Of Seralutinib's Phase 3 Readout (NASDAQ:GOSS) Seeking Alpha

Gossamer Bio and Chiesi Group to collaborate in therapy for lung condition - Reuters

Gossamer Bio and Chiesi Group to collaborate in therapy for lung condition Reuters

Chiesi Inks Potential $486M Deal with Gossamer Bio for Blood Pressure Treatment - BioSpace

Chiesi Inks Potential $486M Deal with Gossamer Bio for Blood Pressure Treatment BioSpace

Gossamer Bio Is A Good Speculative 'Buy' On Seralutinib For PAH And PH-ILD (NASDAQ:GOSS) - Seeking Alpha

Gossamer Bio Is A Good Speculative 'Buy' On Seralutinib For PAH And PH-ILD (NASDAQ:GOSS) Seeking Alpha

Gossamer Bio Has One More Shot On Goal And Is Not Likely To Miss (NASDAQ:GOSS) - Seeking Alpha

Gossamer Bio Has One More Shot On Goal And Is Not Likely To Miss (NASDAQ:GOSS) Seeking Alpha

XOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Business Achievements - GlobeNewswire

XOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Business Achievements GlobeNewswire

Gossamer Bio's DP2 inhibitor GB001 fails 2 midphase trials - Fierce Biotech

Gossamer Bio's DP2 inhibitor GB001 fails 2 midphase trials Fierce Biotech

Gossamer Bio pulls off $276M IPO to push a trio of programs through the clinic - Fierce Biotech

Gossamer Bio pulls off $276M IPO to push a trio of programs through the clinic Fierce Biotech

Top Gossamer Bio Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant